Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses

被引:29
作者
Davis, JL
Salmon, JH
Papich, MG
机构
[1] N Carolina State Univ, Dept Mol & Biomed Sci, Clin Pharmacol Lab, Raleigh, NC 27606 USA
[2] N Carolina State Univ, Coll Vet Med, Dept Clin Sci, Comparat Ophthalmol Lab, Raleigh, NC 27606 USA
关键词
IN-VITRO ACTIVITY; FLUID CONCENTRATIONS; AMPHOTERICIN-B; BODY-FLUID; DISPOSITION; THERAPY; PLASMA; KETOCONAZOLE; EFFICACY; FUNGI;
D O I
10.2460/ajvr.2005.66.1694
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Objective-To determine the pharmacokinetics of itraconazole after IV or oral administration of a solution or capsules to horses and to examine disposition of itraconazole in the interstitial fluid (ISF), aqueous humor, and polymorphonuclear leukocytes after oral administration of the solution. Animals-6 healthy horses. Procedure-Horses were administered itraconazole solution (5 mg/kg) by nasogastric tube, and samples of plasma, ISF, aqueous humor, and leukocytes were obtained. Horses were then administered itraconazole capsules (5 mg/kg), and plasma was obtained. Three horses were administered itraconazole (1.5 mg/kg, IV), and plasma samples were obtained. All samples were analyzed by use of high-performance liquid chromatography. Plasma protein binding was determined. Data were analyzed by compartmental and noncompartmental pharmacokinetic methods. Results-Itraconazole reached higher mean +/- SD plasma concentrations after administration of the solution (0.41 +/- 0.13 mu g/mL) versus the capsules (0.15 +/- 0.12 mu g/mL). Bioavailability after administration of capsules relative to solution was 33.83 +/- 33.08%. Similar to other species, itraconazole has a high volume of distribution (6.3 +/- 0.94 L/kg) and a long half-life (11.3 +/- 2.84 hours). Itraconazole was not detected in the ISF, aqueous humor, or leukocytes. Plasma protein binding was 98.81 +/- 0.17%. Conclusions and Clinical Relevance-Itraconazole administered orally as a solution had higher, more consistent absorption than orally administered capsules and attained plasma concentrations that are inhibitory against fungi that infect horses. Administration of itraconazole solution (5 mg/kg, PO, q 24 h) is suggested for use in clinical trials to test the efficacy of itraconazole in horses.
引用
收藏
页码:1694 / 1701
页数:8
相关论文
共 41 条
[31]   LEVELS OF ITRACONAZOLE IN SKIN BLISTER FLUID AFTER A SINGLE ORAL DOSE AND DURING REPETITIVE ADMINISTRATION [J].
SCHAFERKORTING, M ;
KORTING, HC ;
LUKACS, A ;
HEYKANTS, J ;
BEHRENDT, H .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1990, 22 (02) :211-215
[32]   INFLUENCE OF ALBUMIN ON ITRACONAZOLE AND KETOCONAZOLE ANTIFUNGAL ACTIVITY - RESULTS OF A DYNAMIC INVITRO STUDY [J].
SCHAFERKORTING, M ;
KORTING, HC ;
AMANN, F ;
PEUSER, R ;
LUKACS, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (10) :2053-2056
[33]   INFLUENCE OF SERUM-PROTEIN BINDING ON THE IN-VITRO ACTIVITY OF ANTIFUNGAL AGENTS [J].
SCHAFERKORTING, M ;
KORTING, HC ;
RITTLER, W ;
OBERMULLER, W .
INFECTION, 1995, 23 (05) :292-297
[34]  
Serrano MD, 2003, DIAGN MICR INFEC DIS, V45, P131
[35]   Itraconazole in cyclodextrin solution [J].
Stevens, DA .
PHARMACOTHERAPY, 1999, 19 (05) :603-611
[36]   Solubilizing excipients in oral and injectable formulations [J].
Strickley, RG .
PHARMACEUTICAL RESEARCH, 2004, 21 (02) :201-230
[37]  
Vanden Bossche H, 2003, J VET PHARMACOL THER, V26, P5, DOI 10.1046/j.1365-2885.2003.00456.x
[38]  
Vanden Bossche H, 1985, Curr Top Med Mycol, V1, P313
[39]   Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics [J].
Willems, L ;
van der Geest, R ;
de Beule, K .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2001, 26 (03) :159-169
[40]   DETERMINATION OF ITRACONAZOLE IN PLASMA AND ANIMAL-TISSUES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
WOESTENBORGHS, R ;
LORREYNE, W ;
HEYKANTS, J .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 413 :332-337